Dr. Jones is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Main Street Suite 520
Cambridge, MA 02142
Education & Training
Ohio State University Fisher College of BusinessMBA, 2015 - 2017- University of Texas School of Public HealthMPH, 2004 - 2006
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Michigan Medical SchoolClass of 2000
Certifications & Licensure
NY State Medical License 2018 - 2025
NJ State Medical License 2017 - 2023
OH State Medical License 2006 - 2018
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 1 citationsA west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.Jian Gu, Lisly Chery, Graciela M Nogueras González, Chad Huff, Sara Strom
The Prostate. 2024-05-01 - 14 citationsSafety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Ross A Soo
Journal of Clinical Oncology. 2023-09-10 - 4 citationsPersistent organic pollutants promote aggressiveness in prostate cancer.Julio Buñay, Myriam Kossai, Christelle Damon-Soubeyrant, Angélique De Haze, Jean-Paul Saru
Oncogene. 2023-09-01
Journal Articles
- Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical TrialsSteven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaJeffrey A Jones, William Wierda, Clinical Cancer Research
Press Mentions
- Shop TalkNovember 25th, 2017
Idelalisib Use Expands with New CLL Indication PendingJuly 30th, 2015
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsAugust 6th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
